PMID- 29205349
OWN - NLM
STAT- MEDLINE
DCOM- 20180724
LR  - 20240102
IS  - 1096-9098 (Electronic)
IS  - 0022-4790 (Linking)
VI  - 117
IP  - 6
DP  - 2018 May
TI  - Perioperative cytokine levels portend early death after pancreatectomy for ductal 
      adenocarcinoma.
PG  - 1260-1266
LID - 10.1002/jso.24940 [doi]
AB  - BACKGROUND: Soluble signaling molecules may play an important role in malignant 
      pathogenesis. We hypothesize that perioperative cytokine levels are associated 
      with outcomes in patients with pancreatic adenocarcinoma (PDAC) undergoing 
      surgical resection. METHODS: One hundered and eighteen patients with benign or 
      malignant pancreatic disease were enrolled in a prospective study through a 
      protocol for banking biologic samples. Peripheral blood was drawn at time of 
      operation, and a multiplex cytokine assay was performed. Statistical analysis was 
      via chi(2) and Kaplan Meier methods. RESULTS: Of 118 patients enrolled, 85 (72%) 
      had a diagnosis of PDAC, and 60 (70%) ultimately underwent partial 
      pancreatectomy. Cytokine levels were not associated with postoperative 
      complications in this initial cohort. A plasma level of monocyte chemoattractant 
      protein-1 (MCP-1) pg/mL </=118 was associated with better overall survival (OS) 
      (median survival 21 months vs 12.8 months, P = 0.023), as was non-detectable 
      interleukin-8 (IL-8) (19 months) versus detectable IL-8 (12.8 months, P = 0.05). 
      Patients with both MCP-1 >118 pg/mL and detectable IL-8 had a median survival of 
      10.6 months (P = 0.028). CONCLUSIONS: MCP-1 and IL-8 cytokine levels are 
      associated with decreased survival following pancreatectomy for PDAC, and may be 
      useful biomarkers. Measurement of these cytokine levels at different time points 
      in future investigations will be important to validate these findings.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Lewis, Heather L
AU  - Lewis HL
AUID- ORCID: 0000-0003-4677-3407
AD  - Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, Ohio 
      State University, Columbus, Ohio.
FAU - Chakedis, Jeff M
AU  - Chakedis JM
AD  - Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, Ohio 
      State University, Columbus, Ohio.
FAU - Talbert, Erin
AU  - Talbert E
AD  - Center for Regenerative Medicine and Cell Based Therapies, College of Medicine, 
      Ohio State University, Columbus, Ohio.
FAU - Haverick, Ericka
AU  - Haverick E
AD  - Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, Ohio 
      State University, Columbus, Ohio.
FAU - Rajasekera, Priyani
AU  - Rajasekera P
AD  - Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, Ohio 
      State University, Columbus, Ohio.
FAU - Hart, Philip
AU  - Hart P
AD  - Department of Gastroenterology, Wexner Medical Center, Ohio State University, 
      Columbus, Ohio.
FAU - Bloomston, Mark
AU  - Bloomston M
AD  - 21st Century Oncology, Inc., Fort Meyers, Florida.
FAU - Dillhoff, Mary
AU  - Dillhoff M
AD  - Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, Ohio 
      State University, Columbus, Ohio.
FAU - Pawlik, Timothy M
AU  - Pawlik TM
AUID- ORCID: 0000-0002-4828-8096
AD  - Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, Ohio 
      State University, Columbus, Ohio.
FAU - Guttridge, Denis
AU  - Guttridge D
AD  - Center for Regenerative Medicine and Cell Based Therapies, College of Medicine, 
      Ohio State University, Columbus, Ohio.
FAU - Schmidt, Carl R
AU  - Schmidt CR
AUID- ORCID: 0000-0001-8863-7409
AD  - Division of Surgical Oncology, Department of Surgery, Wexner Medical Center, Ohio 
      State University, Columbus, Ohio.
LA  - eng
PT  - Journal Article
DEP - 20171204
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CXCL8 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-8)
SB  - IM
MH  - Adenocarcinoma/blood/*mortality/surgery
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Carcinoma, Pancreatic Ductal/blood/*mortality/surgery
MH  - Chemokine CCL2/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Interleukin-8/*blood
MH  - Male
MH  - Pancreatectomy/*mortality
MH  - Pancreatic Neoplasms/blood/*mortality/surgery
MH  - Perioperative Care
MH  - Postoperative Complications
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Rate
OTO - NOTNLM
OT  - IL-8
OT  - MCP-1
OT  - cytokines
OT  - pancreatectomy
OT  - pancreatic adenocarcinoma
EDAT- 2017/12/06 06:00
MHDA- 2018/07/25 06:00
CRDT- 2017/12/06 06:00
PHST- 2017/09/03 00:00 [received]
PHST- 2017/11/05 00:00 [accepted]
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2018/07/25 06:00 [medline]
PHST- 2017/12/06 06:00 [entrez]
AID - 10.1002/jso.24940 [doi]
PST - ppublish
SO  - J Surg Oncol. 2018 May;117(6):1260-1266. doi: 10.1002/jso.24940. Epub 2017 Dec 4.